In conclusion, we propose the hypothesis that EA therapy could modulate BPS pain sensitivity by regulating the BDNF–TrkB pathway by diminishing the release of inflammatory factors. This evidence concerns the gene BDNF and Bartsocas-Papas syndrome 1.